These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22270106)

  • 1. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.
    Townsend AR; Bishnoi S; Broadbridge V; Beeke C; Karapetis CS; Jain K; Luke C; Padbury R; Price TJ
    Am J Clin Oncol; 2013 Feb; 36(1):49-52. PubMed ID: 22270106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
    Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG
    J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
    Benavides M; Pericay C; Valladares-Ayerbes M; Gil-Calle S; Massutí B; Aparicio J; Dueñas R; González-Flores E; Carrato A; Marcuello E; Gómez A; Cabrera E; Queralt B; Gómez MJ; Guasch I; Etxeberría A; Alfaro J; Campos JM; Reina JJ; Aranda E
    Clin Colorectal Cancer; 2012 Sep; 11(3):200-6. PubMed ID: 22421001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.
    Kumar R; Jain K; Beeke C; Price TJ; Townsend AR; Padbury R; Roder D; Young GP; Richards A; Karapetis CS
    Cancer; 2013 Feb; 119(4):722-8. PubMed ID: 22990939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment.
    Kim JJ; Kang J; Hong YS; Kim KP; Kim SY; Kim TW; Kim JE
    Med Oncol; 2018 Apr; 35(5):65. PubMed ID: 29623500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
    Chong LC; Hardingham JE; Townsend AR; Piantadosi C; Rico GT; Karapetis C; Padbury R; Maddern G; Roy A; Price TJ
    Target Oncol; 2020 Dec; 15(6):751-757. PubMed ID: 33068283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on chemotherapy for advanced colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):11-5. PubMed ID: 11301834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review.
    Reddy TP; Khan U; Burns EA; Abdelrahim M
    World J Clin Oncol; 2020 Nov; 11(11):959-967. PubMed ID: 33312889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
    Nielsen DL; Palshof JA; Larsen FO; Jensen BV; Pfeiffer P
    Cancer Treat Rev; 2014 Jul; 40(6):701-15. PubMed ID: 24731471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.